JERSEY CITY, N.J., Sept. 26, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovativetherapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present an overview of its pipeline at IDWeek 2018, October 3-7, 2018 in San Francisco.
SCYNEXIS is developing ibrexafungerp (formerly SCY-078) for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. Ibrexafungerp is the first representative of a novel class of structurally distinct glucan synthase inhibitors, triterpenoids. It has demonstrated broad spectrum antifungal activity in vitro and in vivo against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. Ibrexafungerp also demonstrated high clinical cure and mycological eradication rates in a Phase 2b dose-finding study (the DOVE study) evaluating the oral formulation of the agent for the treatment of VVC. The FDA has granted QIDP and Fast Track designations for both the oral and intravenous formulations of ibrexafungerp for the indications of IC (including candidemia), IA and VVC, and has granted Orphan Drug Designation for the IC and IA indications.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
Investor RelationsNatalie WildenradtArgot PartnersTel: firstname.lastname@example.org
Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-an-overview-of-the-companys-pipeline-at-idweek-2018-300717887.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!
FDA approved elapegademase-lvlr injection for intramuscular use is used as an enzyme replacement ...
Armpit lumps and raised bumps in the armpits caused by infection, cysts and other types of ...
Bad eating habits will affect your health as well as your skin and make you look older than your ...View All